Insider trading

Period: 120 months Stock: BTAI Minimum amount: $100K × + Add filter Clear all
Views & alerts

Save your view. Keep the filter you have built, and get an email when a new filing matches it. A free account does both.

When

Period

How far back the list reaches. Filings arrive days after the trade, so the newest rows always lag a little.

28 decisions over 120 months
Who

Role

The position the person holds at the company, read from the title on the filing. A chief executive who is also a director counts as the chief executive.

28 decisions over 120 months
The trade

Type of trade

Purchases, sales, or cluster buys: companies where 3 or more insiders bought within 30 days. The number beside each is what that choice would give.

28 decisions over 120 months
The trade

Minimum amount

Hides rows under this value. The amount is the shares traded times the price on the filing.

28 decisions over 120 months Remove this filter
The trade

Plan

  • Discretionary: they chose to sell that week.
  • Scheduled: a 10b5-1 plan fixed the sale months in advance, so the timing says nothing about what they knew.
  • Not stated: filed before the SEC added the box in April 2023, which is most of the older half of this database.
28 decisions over 120 months
The trade

Share of their own holding

How much of what they already held the trade moved. Selling a tenth of a stake is not the same act as selling all of it.

At least
28 decisions over 120 months
Ownership

What the chief executive holds

The value of the chief executive’s stock measured against base salary. The salary comes from the company’s own proxy. Companies with no figure are in neither direction.

28 decisions over 120 months
Stock
Insider
Type ?
Why it stands out
5 Jun 2024
Mehta Vimal CEO and President · indirect
Sold at will 2×
$199.62K 409,136 at 0.49
100%
Sold half or more
4 Jun 2024
Mehta Vimal CEO and President · indirect
Sold at will 3×
$205.52K 1,018,358 at 0.20
78.2%
Sold half or more
16 Jun 2023
Mehta Vimal CEO and President
Sold on a plan 3×
$605.50K 30,000 at 20.18
42.9%
Planned (10b5-1)
15 Jun 2023
Mehta Vimal CEO and President
Sold on a plan 2×
$646.23K 30,000 at 21.54
42.9%
Planned (10b5-1)
22 May 2023
Mehta Vimal CEO and President
Sold on a plan
$167.64K 6,500 at 25.79
14.8%
Planned (10b5-1)
15 May 2023
Steinhart Richard I Chief Financial Officer
Sold on a plan
$135.86K 5,000 at 27.17
76.9%
Sold half or more
6 Apr 2023
Sold on a plan
$1.04M 60,000 at 17.32
100%
Sold half or more
21 Mar 2023
Mehta Vimal CEO and President
Sold at will 2×
$591.41K 30,000 at 19.71
65.4%
Sold half or more
20 Mar 2023
Mehta Vimal CEO and President
Sold at will 4×
$631.91K 34,500 at 18.32
68.5%
Sold half or more
20 Jan 2023
Yocca Frank Chief Scientific Officer
Sold, plan not stated
$1.50M 50,000 at 30.00
85.6%
Sold half or more
20 Jan 2023
O'Neill Vincent Chief Medical Officer
Sold, plan not stated
$891.39K 29,713 at 30.00
100%
Sold half or more
5 Jan 2023
Sold, plan not stated 2×
$578.33K 25,889 at 22.34
100%
Sold half or more
4 Jan 2023
Sold, plan not stated 2×
$742.55K 34,111 at 21.77
100%
Sold half or more
16 Dec 2022
Mehta Vimal CEO and President
Sold, plan not stated 2×
$583.32K 30,000 at 19.44
75.1%
Sold half or more
15 Dec 2022
Mehta Vimal CEO and President
Sold, plan not stated 2×
$598.18K 30,000 at 19.94
75.1%
Sold half or more
11 Nov 2022
Sold, plan not stated
$488.25K 32,550 at 15.00
100%
Sold half or more
10 Nov 2022
Sold, plan not stated
$411.75K 27,450 at 15.00
100%
Sold half or more
25 Jun 2021
BioXcel Holdings, Inc. 10% owner · indirect
Sold, plan not stated
$14.59M 473,250 at 30.83
5.2%
25 Jun 2021
BioXcel LLC 10% owner
Sold, plan not stated
$14.59M 473,250 at 30.83
5.2%
25 Jun 2021
Nandabalan Krishnan Director · indirect
Sold, plan not stated
$14.59M 473,250 at 30.83
5.2%
25 Jun 2021
Mehta Vimal CEO, President and Secretary · indirect
Sold, plan not stated
$14.59M 473,250 at 30.83
5.2%
15 Mar 2021
Yocca Frank Chief Scientific Officer
Sold, plan not stated 2×
$727.57K 15,000 at 48.50
20.4%
17 Feb 2021
O'Neill Vincent Chief Medical Officer
Sold, plan not stated 5×
$1.39M 25,000 at 55.58
100%
Sold half or more
16 Feb 2021
Yocca Frank Chief Scientific Officer
Sold, plan not stated 7×
$865.15K 15,000 at 57.68
17.0%
1 Feb 2021
Steinhart Richard I Chief Financial Officer
Sold, plan not stated
$180.56K 3,750 at 48.15
71.4%
Sold half or more
25 Jan 2021
Yocca Frank Chief Scientific Officer
Sold, plan not stated 4×
$725.81K 15,000 at 48.39
14.5%
19 Jan 2021
O'Neill Vincent Chief Medical Officer
Sold, plan not stated 5×
$1.24M 25,000 at 49.47
100%
Sold half or more
28 Dec 2020
O'Neill Vincent Chief Medical Officer
Sold, plan not stated 4×
$1.29M 25,000 at 51.45
100%
Sold half or more
Showing 1–28 of 28.